Dec 16, 2019 / 01:00PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Sesen Bio regulatory update. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Dr. Chad Myskiw. Please go ahead, sir.
Chad Myskiw - Sesen Bio, Inc. - Senior Director of Strategic Planning
Thank you, and good morning. Welcome to today's conference call to discuss our update on regulatory activities related to Vicinium. On the call with me today are Dr. Thomas Cannell, President and CEO; and Monica Forbes, Chief Financial Officer.
On December 9, we issued a press release detailing the initiation of our BLA submission for Vicinium. The press release and the slides to which we will refer are available on the Investors section of the company's website at sesenbio.com.
Today's discussion will include forward-looking statements related to the company's current plans and expectations, which are subject to risks and uncertainties. Actual results may
Sesen Bio, Inc. - Special Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
